A Case of simultaneous occurrence of Marine – Lenhart syndrome and a papillary thyroid microcarcinoma
© Scherer et al.; licensee BioMed Central Ltd. 2013
Received: 9 November 2012
Accepted: 23 April 2013
Published: 8 May 2013
Marine-Lenhart syndrome is defined as the co-occurrence of Graves’ disease and functional nodules. The vast majority of autonomous adenomas are benign, whereas functional thyroid carcinomas are considered to be rare. Here, we describe a case of simultaneous occurrence of Marine-Lenhart syndrome and a papillary microcarcinoma embedded in a functional nodule.
A 55 year-old, caucasian man presented with overt hyperthyroidism (thyrotropin (TSH) <0.01 μIU/L; free thyroxine (FT4) 3.03 ng/dL), negative thyroid peroxidase and thyroglobulin autoantibodies, but elevated thyroid stimulating hormone receptor antibodies (TSH-RAb 2.6 IU/L). Ultrasound showed a highly vascularized hypoechoic nodule (1.1 × 0.9 × 2 cm) in the right lobe, which projected onto a hot area detected in the 99mtechnetium thyroid nuclear scan. Overall uptake was increased (4.29%), while the left lobe showed lower tracer uptake with no visible background-activity, supporting the notion that both Graves’ disease and a toxic adenoma were present. After normal thyroid function was reinstalled with methimazole, the patient underwent thyroidectomy. Histological work up revealed a unifocal papillary microcarcinoma (9 mm, pT1a, R0), positively tested for the BRAF V600E mutation, embedded into the hyperfunctional nodular goiter.
Neither the finding of an autonomously functioning thyroid nodule nor the presence of Graves’ disease rule out papillary thyroid carcinoma.
KeywordsToxic adenoma Graves’ disease Marine-Lenhart syndrome Papillary carcinoma Hyperthyroidism
The eponym Marine-Lenhart syndrome is typically used for the rare condition of concurrent manifestation of Graves’ disease and thyroid autonomy (Plummer’s disease) [1–3]. In general, the majority of autonomic adenomas of the thyroid are benign, whereas autonomic thyroid carcinomas are considered a relatively rare finding [4, 5]. Here, we report the exceptional case of simultaneous occurrence of Marine-Lenhart syndrome and a papillary microcarcinoma, which was embedded in an autonomous adenoma.
Follow up 1 (after 3 weeks)
Follow up 2 (after 9 weeks)
Post surgical (after 17 weeks)
FT4 (0.76 – 1.66 ng/dL)
TSH (0.44 – 3.77 μIU/mL)
TT4 (58 – 124 ng/mL)
TT3 (0.8 – 1.8 ng/mL)
TgAb (< 33 IU/mL)
TPO (< 28 IU/mL)
TSH-RAb (< 1.75 IU/L)
TBG (14 – 32 μg/mL)
Tg (1.6 – 55 ng/mL)
Calcitonin (< 8 pg/mL)
A postoperative follow up 17 weeks after the initial diagnosis showed subclinical hypothyroidism, which was fixed by adjusting the levothyroxine therapy (Table 1). Notably, the patient developed a moderately active orbitopathy postoperatively, which was treated with IV corticosteroids for 3 months.
The BRAF V600E mutation is usually associated with higher malignancy and aggressiveness in papillary thyroid carcinomas  and in most cases with typical ultrasound features of thyroid malignancy . However, due to the unifocality of the lesion and the fact that the papillary carcinoma in our patient measured less than 10 mm, according to the 2009 consensus of the American Thyroid Association no radioiodine therapy was performed . Therefore, postsurgical thyroglobulin (TG) levels are still detectable in our patient (Table 1) and only of limited use in postsurgical follow up.
It is commonly believed that papillary microcarcinomas only rarely collocate within toxic thyroid adenomas, although several case reports are found in the literature [9–16]. A selection of retrospective studies estimate the risk of concurrent papillary carcinomas in functioning nodules ranging from 0.34% up to 5% [5, 17, 18]. In a cohort of US children with toxic adenoma the malignancy rate was yet higher (about 11%) . Thus, despite the relatively low risk of malignant transformation of functioning nodules, these lesions need careful clinical follow up with ultrasound and possibly fine needle aspiration biopsy especially when patients are young.
Furthermore, it is still subject of debate whether the frequency of thyroid cancer is higher in patients with Graves’ disease, mostly because the studies are typically retrospective and extend over a long period of time, where diagnostic capabilities and tools might have changed significantly (extensively reviewed in ). However, it seems that the prevalence of palpable nodules is about 3-fold higher in Graves’ patients (15.8%)  compared to the general population living in a non-endemic region (5%) . Studies relying on ultrasound imaging also find a higher prevalence for thyroid nodules in patients suffering form Graves’ disease (33.6%)  compared to the general population (about 26%) although to a lesser extent [24, 25]. Of note, in the former study more than half the patients suffering from Graves’ disease developed thyroid nodules during the 2-year follow up, which suggests that Graves’ disease promotes de novo thyroid nodule formation . Furthermore, the mean malignancy rate of palpable nodules in Graves’ patients is about 16% versus a 5% malignancy rate in the general population (reviewed in ). Thus, in conjunction with the above-mentioned prevalence rates of thyroid nodules, it can be estimated that Graves’ patients have an almost 10-fold higher chance of developing thyroid cancer. In a retrospective multicenter study with more than 500 Graves’ patients thyroid carcinomas were found in 3.8% (20 out of 21 were papillary carcinomas) . Another study matched these results and found a malignancy rate of 3.3% in their collective of Graves’ patients , whereas the incidence of thyroid cancer in the general US population was estimated at about 14.4 per 100,000 . Of note, in the former study all papillary carcinomas were detected within thyroid nodules embedded into a Graves’ goiter. In total 15% of the patients suffering from both, nodules and Graves’ disease, also had thyroid carcinomas . In another study the risk for malignancy of a thyroid nodule within a toxic diffuse goiter even reached 22% , therefore any nodule within a Graves’ goiter should be carefully examined to rule out a thyroid carcinoma.
There is evidence that thyroid cancer in Graves’ patients is more aggressive. Therefore, an important question is, whether the presence of Graves’ disease in thyroid cancer patients affects their clinical outcome. Studies have found that in Graves’ patients thyroid carcinomas grow more invasively and develop lymph node and distant metastases more frequently compared to euthyroid controls [31–33], although a more recent study was not able to confirm these data . Yet, given the possibility that Graves’ disease increases nodule formation and their respective risk for malignant transformation, it is conceivable that Graves’ disease may constitute an additional risk factor when managing thyroid cancer patients lowering the threshold for surgical intervention.
Color flow Doppler sonography has proven a useful tool in the differential diagnosis of toxic multinodular goiter. Boi et al. have indicated that hyperthyroid patients with multinodular goiter can be subdivided into two distinct groups using color flow Doppler patterns: 1) Nodules with normal vascularization surrounded by hypervascularized hypoechoic thyroid tissue showing a similar picture as in Graves’ patients. Notably, in 44% of these patients TSH receptor antibodies were elevated; and 2) heterogenous hypervascularized nodules embedded into normoechoic-normovascular thyroid parenchyma. None of these patients were tested positive for TSH receptor antibodies . The first group constitutes a group of patients, who probably developed Graves’ disease in a non-toxic multinodular goiter. Our patient on the other hand showed features of both groups. His prominent nodule was heterogeneous and clearly more vascularized compared to the surrounding thyroid parenchyma matching the ultrasound criteria of group 2). However, his TSH receptor antibody titers were also elevated, indicating that both thyroid autonomy and Graves’ disease are concurrent.
Finally, hyperthyroid patients have a disproportionate increase in T3 compared to T4 levels . Laurberg et al. have found that this probably results from a relative increase in type 1 iodothyronine deiodinase activity in hyperthyroid patients compared to healthy subjects, where type 2 iodothyronine deiodinase accounts for the majority of T3 production [37, 38]. Our patient with Marine-Lenhart syndrome also presented with an increased T3 to T4 ratio of 1.9%. This matches what Laurberg et al. have found in their collective of multinodular toxic goiter. Their patients with thyroid autonomy had a lower T3/T4 ratio compared to those with Graves’ disease (2.0 versus 2.7%) , suggesting that in our patient the autonomous adenoma was the more prominent component of disease, which is also supported by the relatively low levels of circulating TSH-RAb and thyroid uptake in the region outside of the adenoma.
Taken together, neither the finding of an autonomously functioning thyroid nodule nor the presence of Graves’ disease can rule out a papillary thyroid carcinoma. Although, there is still some debate whether Graves’ disease increases the risk for thyroid cancer, nodules embedded in a Graves’ goiter should be carefully evaluated for malignant transformation especially when patients are young.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Series Editor of this journal.
Thyrotropin or thyroid-stimulating hormone
Thyroid stimulating hormone receptor antibody
- Biersack HJ, Biermann K: The Marine-Lenhart syndrome revisited. Wien Klin Wochenschr. 2011, 123: 459-462. 10.1007/s00508-011-0029-5.View ArticlePubMed
- Charkes ND: Graves’ disease with functioning nodules (Marine-Lenhart syndrome). J Nucl Med. 1972, 13: 885-892.PubMed
- Marine D, Lenhart CH: Pathological anatomy of exophthalmic goiter: the anatomical and physiological relations of the thyroid gland to the disease; the treatment. Arch Intern Med. 1911, VIII: 265-316. 10.1001/archinte.1911.00060090002001.View Article
- Harach HR, Sanchez SS, Williams ED: Pathology of the autonomously functioning (hot) thyroid nodule. Ann Diagn Pathol. 2002, 6: 10-19. 10.1053/adpa.2002.30605.View ArticlePubMed
- Erdogan MF, Anil C, Ozer D, Kamel N, Erdogan G: Is it useful to routinely biopsy hot nodules in iodine deficient areas?. J Endocrinol Invest. 2003, 26: 128-131.View ArticlePubMed
- Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008, 15: 191-205. 10.1677/ERC-07-0212.View ArticlePubMed
- Kabaker AS, Tublin ME, Nikiforov YE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Carty SE, Yip L: Suspicious Ultrasound Characteristics Predict BRAF V600E-Positive Papillary Thyroid Carcinoma. Thyroid. 2012, 22 (6): 585-589. 10.1089/thy.2011.0274.. Epub 2012 Apr 23PubMed CentralView ArticlePubMed
- Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009, 19: 1167-1214. 10.1089/thy.2009.0110.View ArticlePubMed
- De Rosa G, Testa A, Maurizi M, Satta MA, Aimoni C, Artuso A, Silvestri E, Rufini V, Troncone L: Thyroid carcinoma mimicking a toxic adenoma. Eur J Nucl Med. 1990, 17: 179-184. 10.1007/BF00811447.View ArticlePubMed
- Kim TS, Asato R, Akamizu T, Harada D, Nakashima Y, Higashi T, Yamamoto N, Tamura Y, Tamaki H, Hirano S, Tanaka S, Ito J: A rare case of hyperfunctioning papillary carcinoma of the thyroid gland. Acta Otolaryngol Suppl. 2007, 557: 55-57.View ArticlePubMed
- Lamberg BA, Makinen J, Murtomaa M: Papillary thyroid carcinoma in a toxic adenoma. Nuklearmedizin. 1976, 15: 138-141.PubMed
- Laroche C, Cremer GA, Sereni D, Dero M: Papillary thyroid cancer lying within a toxic adenoma (author’s transl). Ann Med Interne (Paris). 1979, 130: 675-678.
- Majima T, Doi K, Komatsu Y, Itoh H, Fukao A, Shigemoto M, Takagi C, Corners J, Mizuta N, Kato R, Nakao K: Papillary thyroid carcinoma without metastases manifesting as an autonomously functioning thyroid nodule. Endocr J. 2005, 52: 309-316. 10.1507/endocrj.52.309.View ArticlePubMed
- Nishida AT, Hirano S, Asato R, Tanaka S, Kitani Y, Honda N, Fujiki N, Miyata K, Fukushima H, Ito J: Multifocal hyperfunctioning thyroid carcinoma without metastases. Auris Nasus Larynx. 2008, 35: 432-436. 10.1016/j.anl.2007.07.008.View ArticlePubMed
- Tfayli HM, Teot LA, Indyk JA, Witchel SF: Papillary thyroid carcinoma in an autonomous hyperfunctioning thyroid nodule: case report and review of the literature. Thyroid. 2010, 20: 1029-1032. 10.1089/thy.2010.0144.PubMed CentralView ArticlePubMed
- Uludag M, Yetkin G, Citgez B, Isgor A, Basak T: Autonomously functioning thyroid nodule treated with radioactive iodine and later diagnosed as papillary thyroid cancer. Hormones (Athens). 2008, 7: 175-179.
- Rosler H, Wimpfheimer C, Ruchti C, Kinser J, Teuscher J: Hyperthyroidism in thyroid cancer. Retrospective study of 53 cases. Nuklearmedizin. 1984, 23: 293-300.PubMed
- Mizukami Y, Michigishi T, Nonomura A, Yokoyama K, Noguchi M, Hashimoto T, Nakamura S, Ishizaki T: Autonomously functioning (hot) nodule of the thyroid gland. A clinical and histopathologic study of 17 cases. Am J Clin Pathol. 1994, 101: 29-35.PubMed
- Croom RD, Thomas CG, Reddick RL, Tawil MT: Autonomously functioning thyroid nodules in childhood and adolescence. Surgery. 1987, 102: 1101-1108.PubMed
- Pazaitou-Panayiotou K, Michalakis K, Paschke R: Thyroid cancer in patients with hyperthyroidism. Horm Metab Res. 2012, 44: 255-262.View ArticlePubMed
- Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. 1974, 38: 976-998. 10.1210/jcem-38-6-976.View ArticlePubMed
- Vander JB, Gaston EA, Dawber TR: The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968, 69: 537-540. 10.7326/0003-4819-69-3-537.View ArticlePubMed
- Cantalamessa L, Baldini M, Orsatti A, Meroni L, Amodei V, Castagnone D: Thyroid nodules in Graves disease and the risk of thyroid carcinoma. Arch Intern Med. 1999, 159: 1705-1708. 10.1001/archinte.159.15.1705.View ArticlePubMed
- Brander A, Viikinkoski P, Nickels J, Kivisaari L: Thyroid gland: US screening in a random adult population. Radiology. 1991, 181: 683-687.View ArticlePubMed
- Chung WY, Chang HS, Kim EK, Park CS: Ultrasonographic mass screening for thyroid carcinoma: a study in women scheduled to undergo a breast examination. Surg Today. 2001, 31: 763-767. 10.1007/s005950170044.View ArticlePubMed
- Belfiore A, Russo D, Vigneri R, Filetti S: Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf). 2001, 55: 711-718. 10.1046/j.1365-2265.2001.01415.x.View Article
- Kraimps JL, Bouin-Pineau MH, Mathonnet M, De Calan L, Ronceray J, Visset J, Marechaud R, Barbier J: Multicentre study of thyroid nodules in patients with Graves’ disease. Br J Surg. 2000, 87: 1111-1113. 10.1046/j.1365-2168.2000.01504.x.View ArticlePubMed
- Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, Hong SJ, Shong YK: Ultrasonographic screening for detection of thyroid cancer in patients with Graves’ disease. Clin Endocrinol (Oxf). 2004, 60: 719-725. 10.1111/j.1365-2265.2004.02043.x.View Article
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073.View ArticlePubMed
- Pacini F, Elisei R, Di Coscio GC, Anelli S, Macchia E, Concetti R, Miccoli P, Arganini M, Pinchera A: Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest. 1988, 11: 107-112.View ArticlePubMed
- Ozaki O, Ito K, Kobayashi K, Toshima K, Iwasaki H, Yashiro T: Thyroid carcinoma in Graves’ disease. World J Surg. 1990, 14: 437-440. 10.1007/BF01658550. discussion 440–431View ArticlePubMed
- Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R: Outcome of differentiated thyroid cancer in Graves’ patients. J Clin Endocrinol Metab. 1998, 83: 2805-2809. 10.1210/jc.83.8.2805.PubMed
- Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R: Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab. 1990, 70: 830-835. 10.1210/jcem-70-4-830.View ArticlePubMed
- Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K: Recent outcome of Graves’ disease patients with papillary thyroid cancer. Eur J Endocrinol. 2007, 157: 325-329. 10.1530/EJE-07-0136.View ArticlePubMed
- Boi F, Loy M, Piga M, Serra A, Atzeni F, Mariotti S: The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres. Eur J Endocrinol. 2000, 143: 339-346. 10.1530/eje.0.1430339.View ArticlePubMed
- Nicoloff JT, Low JC, Dussault JH, Fisher DA: Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. J Clin Invest. 1972, 51: 473-483. 10.1172/JCI106835.PubMed CentralView ArticlePubMed
- Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR: Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest. 2005, 115: 2524-2533. 10.1172/JCI25083.PubMed CentralView ArticlePubMed
- Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, Helleberg K, Pedersen KM: Sources of circulating 3,5,3′-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab. 2007, 92: 2149-2156. 10.1210/jc.2007-0178.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6823/13/16/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.